See more : Metallis Resources Inc. (MTS.V) Income Statement Analysis – Financial Results
Complete financial analysis of Pharvaris N.V. (PHVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharvaris N.V., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sunfar Computer Co., Ltd (6154.TWO) Income Statement Analysis – Financial Results
- XRF Scientific Limited (XRF.AX) Income Statement Analysis – Financial Results
- Khaitan (India) Limited (KHAITANLTD.NS) Income Statement Analysis – Financial Results
- At Home Group Inc. (HOME) Income Statement Analysis – Financial Results
- Metso Oyj (METSO.HE) Income Statement Analysis – Financial Results
Pharvaris N.V. (PHVS)
About Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 252.27K | 150.19K | 80.46K | 0.00 | 547.41 | 0.00 |
| Gross Profit | -252.27K | -150.19K | -80.46K | 0.00 | -547.41 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 65.58M | 57.38M | 35.79M | 19.51M | 5.68M | 3.65M |
| General & Administrative | 31.14M | 29.34M | 18.35M | 5.50M | 2.33M | 668.12K |
| Selling & Marketing | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.34M | 29.34M | 18.35M | 5.50M | 2.33M | 668.12K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 96.91M | 86.71M | 54.14M | 25.01M | 8.01M | 4.31M |
| Cost & Expenses | 96.91M | 86.71M | 54.14M | 25.01M | 8.01M | 4.31M |
| Interest Income | 0.00 | 16.11 | 267.51 | 92.47 | 4.38 | 0.00 |
| Interest Expense | 20.06K | 16.11K | 278.18K | 92.47K | 0.00 | 0.00 |
| Depreciation & Amortization | 59.78K | 150.19K | 80.46K | 7.40K | 547.41 | 4.31M |
| EBITDA | -96.85M | -86.58M | -54.06M | -25.01M | -8.01M | -4.31M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -96.91M | -86.74M | -65.90M | -25.01M | -7.99M | -4.31M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.91M | 11.08M | 11.48M | -1.06M | -16.88K | -380.00 |
| Income Before Tax | -99.83M | -75.65M | -42.66M | -26.07M | -8.03M | -4.31M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.05M | 679.09K | 70.12K | -83.25K | 16.88K | 380.00 |
| Net Income | -100.88M | -76.33M | -42.73M | -25.99M | -8.04M | -4.31M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.63 | -2.27 | -1.41 | -0.85 | -1.66 | -0.14 |
| EPS Diluted | -2.63 | -2.27 | -1.41 | -0.85 | -1.66 | -0.14 |
| Weighted Avg Shares Out | 38.39M | 33.59M | 30.41M | 30.52M | 4.85M | 31.84M |
| Weighted Avg Shares Out (Dil) | 38.39M | 33.59M | 30.41M | 30.52M | 4.85M | 31.84M |
Pharvaris Announces Annual Meeting of Shareholders
ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take...
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, recently presented data highlighting the unique pharmacological and clinical properties...
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three...
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the first quarter ended March...
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year...
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief...
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at...
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
ZUG, Switzerland, March 18, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, presented at two recent congresses: the 3rd National Congress of...
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming...
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that its management will participate in the Leerink Global...
Source: https://incomestatements.info
Category: Stock Reports